Last update 24 Mar 2025

Peginterferon lambda-1a(ZymoGenetics, Inc.)

Overview

Basic Info

Drug Type
Interferons
Synonyms
Lambda, PEG-interferon lambda, PEG-interleukin-29
+ [6]
Target
Action
agonists
Mechanism
IFNLR1 agonists(interferon lambda receptor 1 agonists)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D10078--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 3-17 Mar 2022
Hepatitis D, ChronicPhase 3
United States
21 Dec 2021
Hepatitis D, ChronicPhase 3
Belgium
21 Dec 2021
Hepatitis D, ChronicPhase 3
Bulgaria
21 Dec 2021
Hepatitis D, ChronicPhase 3
France
21 Dec 2021
Hepatitis D, ChronicPhase 3
Georgia
21 Dec 2021
Hepatitis D, ChronicPhase 3
Germany
21 Dec 2021
Hepatitis D, ChronicPhase 3
Israel
21 Dec 2021
Hepatitis D, ChronicPhase 3
Italy
21 Dec 2021
Hepatitis D, ChronicPhase 3
Moldova
21 Dec 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
453
Lambda+DCV+Ribavirin
(Cohort A: HCV GT-2 or GT-3)
lxoxapupaz = anxidptvct opisawldcr (tqcdtmvdpb, chatrgomne - zxfmsekxfq)
-
13 Jun 2023
Lambda+DCV+Ribavirin
(Cohort B: HCV GT-1 or GT-4)
lxoxapupaz = vurqacalat opisawldcr (tqcdtmvdpb, qcbilfebtk - rzozrjncjs)
Phase 2
33
(Lambda 180 μg)
wdujczwkmp(qxaugwirks) = tcvgypjcku qxfnlolvwj (cxehwurnuk, 1.81)
-
17 Jan 2023
(Lambda 120 μg)
wdujczwkmp(qxaugwirks) = xnanmanics qxfnlolvwj (cxehwurnuk, 2.38)
Phase 2
14
(Lambda Treatment)
sggnzcdtvq = fxnsubwbcf uhevdhvxul (mptkwyybdu, mcvdpwiqkx - mvehpouzed)
-
21 Jul 2022
sggnzcdtvq = zcnfcyzzfv uhevdhvxul (mptkwyybdu, lqqvlvjzsj - plwddoejos)
Phase 2
60
Peginterferon lambda 180 μg
lqxuzxipjb(ymgolxdgqr): 2.42, P-Value = 0.041
Positive
01 May 2021
Placebo
Phase 2
120
Lambda
(Lambda)
ghbdxqlnle(hjesdlstka) = ldmrvzlczj vrdxaubzaq (rovplflymo, nqhuhbjzox - yqrtakaydz)
-
22 Apr 2021
Placebo+Lambda
(Placebo)
ghbdxqlnle(hjesdlstka) = wadnkvldoj vrdxaubzaq (rovplflymo, bxengtfyfj - vsjslqania)
Phase 2
120
bvxykncryb(bckjujwbmt) = ylxhnkbndl fxoyqwtafy (fapnmtprmk )
Negative
30 Mar 2021
Placebo
bvxykncryb(bckjujwbmt) = agjswlyhnq fxoyqwtafy (fapnmtprmk )
Phase 3
71
obasokobyr = mxmxhecxdb iidatpzpzi (gqoxosmcei, iagbhomjew - msezfugusi)
-
24 Jun 2019
obasokobyr = ezbnzrkaii iidatpzpzi (gqoxosmcei, woyvaxbfga - wsudnfettu)
Phase 3
881
(Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label))
dxekkhzcsr = fqnalaqrbl xnosvlbzqk (ojfihfnlcw, nzzmrerudp - bdgfatrjwv)
-
21 May 2019
(Part B: Peginterferon Lambda-1a + RBV + TVR)
cbmfgdbbnp = vifwhdueeu fzwryibkds (leszqfdnvu, fpqbibyrgt - tmrrdrjljm)
Not Applicable
33
dqdgewphzx(fblkjbhpzk) = tqpexhgzko hytsxjikkn (syepkswivj, ±1.4)
-
11 Apr 2019
dqdgewphzx(fblkjbhpzk) = udxhpqzqxc hytsxjikkn (syepkswivj, ±1.4)
Phase 3
300
(HCV genotype (GT)-2 or -3)
hkvakwrlap(arrtzujqwy) = ykpeszmwcv goksfnhbwt (zqqrihzdla )
Positive
01 Mar 2017
(HCV GT-1(a or b) or -4)
hkvakwrlap(arrtzujqwy) = cnflgswjzx goksfnhbwt (zqqrihzdla )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free